|
CA1138334A
(en)
*
|
1977-10-28 |
1982-12-28 |
Karl Bernauer |
Pharmaceutical preparations containing certain urea derivatives
|
|
MC1220A1
(fr)
*
|
1977-10-28 |
1979-07-20 |
Hoffmann La Roche |
Nouveaux derives d'imidazolidine
|
|
FI801184A7
(fi)
*
|
1979-04-24 |
1981-01-01 |
F Hoffmann La Roche & Co |
Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
|
|
AU594309B2
(en)
*
|
1984-08-02 |
1990-03-08 |
Fernand Labrie |
Pharmaceutical composition for combination therapy of hormonedependent cancers
|
|
US4775660A
(en)
*
|
1984-08-02 |
1988-10-04 |
Fernand Labrie |
Treatment of breast cancer by combination therapy
|
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
|
IT1214735B
(it)
*
|
1986-11-04 |
1990-01-18 |
Roussel Maestretti Spa |
Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
|
|
US5084472A
(en)
*
|
1986-11-04 |
1992-01-28 |
Roussel |
Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
|
|
FR2619381B1
(fr)
*
|
1987-08-13 |
1989-12-08 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
|
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
|
FR2656302B1
(fr)
*
|
1989-12-22 |
1992-05-07 |
Roussel Uclaf |
Nouveau procede de preparation de l'anandron et derives de l'anandron.
|
|
FR2671348B1
(fr)
*
|
1991-01-09 |
1993-03-26 |
Roussel Uclaf |
Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
|
|
FR2693461B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
|
USRE35956E
(en)
*
|
1991-01-09 |
1998-11-10 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
|
US5411981A
(en)
*
|
1991-01-09 |
1995-05-02 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
|
FR2685328B1
(fr)
*
|
1991-12-20 |
1995-12-01 |
Rhone Poulenc Agrochimie |
Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
|
FR2706456B1
(fr)
*
|
1993-06-18 |
1996-06-28 |
Rhone Poulenc Agrochimie |
Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
|
US6002016A
(en)
*
|
1991-12-20 |
1999-12-14 |
Rhone-Poulenc Agrochimie |
Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
|
|
FR2694290B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
|
US6008370A
(en)
*
|
1992-11-25 |
1999-12-28 |
Rhone-Poulenc Agrochimie |
Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
|
|
TW521073B
(en)
*
|
1994-01-05 |
2003-02-21 |
Hoechst Marion Roussel Inc |
New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
|
|
FR2724169B1
(fr)
*
|
1994-09-06 |
1997-01-03 |
Roussel Uclaf |
Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
|
FR2715402B1
(fr)
*
|
1994-01-05 |
1996-10-04 |
Roussel Uclaf |
Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
|
FR2725206B1
(fr)
*
|
1994-09-29 |
1996-12-06 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
|
US5656651A
(en)
*
|
1995-06-16 |
1997-08-12 |
Biophysica Inc. |
Androgenic directed compositions
|
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
US7001911B2
(en)
|
2000-06-28 |
2006-02-21 |
Bristol-Myers Squibb Company |
Fused cyclic modulators of nuclear hormone receptor function
|
|
US20040077605A1
(en)
*
|
2001-06-20 |
2004-04-22 |
Salvati Mark E. |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
|
IL152719A0
(en)
*
|
2000-06-28 |
2003-06-24 |
Bristol Myers Squibb Co |
Selective androgen receptor modulators and methods for their identification
|
|
EP1854798A3
(en)
|
2000-09-19 |
2007-11-28 |
Bristol-Myers Squibb Company |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
|
US6953679B2
(en)
|
2000-09-19 |
2005-10-11 |
Bristol-Myers Squibb Company |
Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
|
|
US20040087548A1
(en)
|
2001-02-27 |
2004-05-06 |
Salvati Mark E. |
Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
|
US7015253B2
(en)
*
|
2001-07-10 |
2006-03-21 |
American Medical Systems, Inc. |
Regimen for treating prostate tissue and surgical kit for use in the regimen
|
|
JP4434740B2
(ja)
|
2001-12-19 |
2010-03-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
核ホルモン受容体機能の調節剤である、縮合ヘテロ環化合物およびその類似体
|
|
FR2850652B1
(fr)
*
|
2003-01-31 |
2008-05-30 |
Aventis Pharma Sa |
Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
|
US7354933B2
(en)
*
|
2003-01-31 |
2008-04-08 |
Aventis Pharma Sa |
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
|
US7816372B2
(en)
*
|
2003-08-22 |
2010-10-19 |
Ligand Pharmaceuticals Incorporated |
6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
|
|
JP2007512359A
(ja)
|
2003-11-19 |
2007-05-17 |
メタバシス・セラピューティクス・インコーポレイテッド |
新規なリン含有甲状腺ホルモン様物質
|
|
DE602004031881D1
(de)
*
|
2003-12-19 |
2011-04-28 |
Univ California |
Verfahren und materialien zur beurteilung von prostatakrebstherapien
|
|
US7718684B2
(en)
*
|
2004-02-24 |
2010-05-18 |
The Regents Of The University Of California |
Methods and materials for assessing prostate cancer therapies and compounds
|
|
WO2005090282A1
(en)
|
2004-03-12 |
2005-09-29 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
ES2422204T3
(es)
*
|
2004-09-10 |
2013-09-09 |
Janssen Pharmaceutica Nv |
Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
RS53967B1
(sr)
|
2005-05-13 |
2015-08-31 |
The Regents Of The University Of California |
Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
|
|
NZ560354A
(en)
*
|
2005-06-17 |
2010-10-29 |
Ligand Pharm Inc |
Androgen receptor modulator compounds and methods
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
FR2896503B1
(fr)
*
|
2006-01-23 |
2012-07-13 |
Aventis Pharma Sa |
Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
|
LT2656841T
(lt)
|
2006-03-27 |
2016-09-26 |
The Regents Of The University Of California |
Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
|
|
MX2008012492A
(es)
|
2006-03-29 |
2008-12-12 |
Univ California |
Compuestos de diariltiohidantoina.
|
|
EP2094643B1
(en)
|
2006-12-01 |
2012-02-29 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
|
ES2721915T3
(es)
|
2007-01-02 |
2019-08-06 |
Aquabeam Llc |
Dispositivos mínimamente invasivos para el tratamiento de enfermedades de la próstata
|
|
US12290277B2
(en)
|
2007-01-02 |
2025-05-06 |
Aquabeam, Llc |
Tissue resection with pressure sensing
|
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
|
US8680291B2
(en)
|
2007-10-26 |
2014-03-25 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
EP2259742B1
(en)
|
2008-03-06 |
2020-01-01 |
AquaBeam LLC |
Tissue ablation and cautery with optical energy carried in fluid stream
|
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
|
FR2944524B1
(fr)
*
|
2009-04-17 |
2012-11-30 |
Ipsen Pharma Sas |
Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
|
|
AU2011218173C1
(en)
|
2010-02-16 |
2015-04-16 |
Aragon Pharmaceuticals, Inc. |
Androgen receptor modulators and uses thereof
|
|
EP2672958A1
(en)
|
2011-02-08 |
2013-12-18 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
CN108606773B
(zh)
|
2012-02-29 |
2020-08-11 |
普罗赛普特生物机器人公司 |
自动化图像引导的组织切除和处理
|
|
UA117663C2
(uk)
|
2012-09-26 |
2018-09-10 |
Арагон Фармасьютікалз, Інк. |
Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
|
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
|
JP6403695B2
(ja)
|
2013-02-14 |
2018-10-10 |
プロセプト バイオロボティクス コーポレイション |
アクアアブレーションアクアビーム眼科手術方法および装置
|
|
EP3327144B1
(en)
|
2013-02-25 |
2020-03-25 |
Novartis AG |
Novel androgen receptor mutation
|
|
EP3041422A4
(en)
|
2013-09-06 |
2017-04-12 |
Procept Biorobotics Corporation |
Automated image-guided tissue resection and treatment
|
|
BR112016031037B1
(pt)
|
2014-06-30 |
2023-02-07 |
Procept Biorobotics Corporation |
Aparelho para ablação de tecido vascular
|
|
BR112017004431B1
(pt)
|
2014-09-05 |
2022-11-01 |
Procept Biorobotics Corporation |
Aparelho para tratar um paciente
|
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
|
US20190209469A1
(en)
|
2016-08-20 |
2019-07-11 |
Ftf Pharma Private Limited |
Pharmaceutical composition comprising an androgen receptor inhibitor
|
|
CN107216290B
(zh)
*
|
2017-06-12 |
2021-03-16 |
陕西科技大学 |
一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
|
|
US10702508B2
(en)
|
2017-10-16 |
2020-07-07 |
Aragon Pharmaceuticals, Inc. |
Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
|
|
CA3133929A1
(en)
|
2019-04-19 |
2020-10-22 |
Lin Zhi |
Crystalline forms and methods of producing crystalline forms of a compound
|